Current Research & Development Activities
Bayer is committed to the discovery, development and commercialization of novel medicines to serve unmet medical needs. Over the past 19 years, Bayer has spent hundreds of millions of dollars on hemophilia research and clinical trials. We as a company are committed to innovative research and development of next-generation therapies that produce significant benefits for the people who are in need of safe and effective treatments.
Long-Acting Recombinant Factor VIII
Currently, the clinical research team is continuing a development program surrounding long-acting recombinant factor VIII products, which may move infusion regimens (currently up to three times per week) to once-weekly infusions for preventive care. Bayer believes factor VIII therapy with prolonged activity will greatly improve the lives of people with hemophilia, making it simpler for them to comply with their treatment regimens.
Improved Factor VIII molecule
Our team of researchers also is applying innovative molecular engineering technologies to develop a recombinant FVIII molecules with improved properties such as increased activity, increased circulation time and reduced immunogenicity1.
1 Immunogenicity – causing or capable of producing an immune response.
